Michael Glenn O'Connor1, Adam Seegmiller2. 1. Department of Pediatrics, Division Pediatric Pulmonary, Allergy, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States. Electronic address: michael.g.oconnor@vanderbilt.edu. 2. Department of Pathology, Microbiology, and Immunology, Vanderbilt University School of Medicine, Nashville, TN, United States.
Abstract
BACKGROUND: Ivacaftor has produced significant improvement in certain individuals with cystic fibrosis (CF), though the full metabolic effects of treatment remain unknown. Abnormalities in fatty acid metabolism have previously been shown to be a characteristic of CFTR dysfunction. We hypothesized that as a reflection of this clinical improvement, ivacaftor would improve plasma fatty acid levels and decrease urine prostaglandin E metabolite levels. METHODS: This study analyzed plasma fatty acid levels and urine prostaglandin E metabolites (PGE-M) in 40 subjects with CF participating in the G551D observational (GOAL) study who demonstrated response to the medication by a significant decrease in sweat Cl levels. Paired samples were analyzed before and after 6months of ivacaftor treatment. RESULTS: Linoleic acid and docosahexaenoic acid levels, which are typically low in individuals with CF, did not significantly increase with ivacaftor treatment. However, arachidonic acid levels did decrease with ivacaftor treatment and there was a significant decrease in the arachidonic acid metabolite PGE-M as measured in the urine [median: before treatment 17.03ng/mg Cr; after treatment 9.06ng/mg Cr; p<0.001]. Furthermore, there were fatty acid age differences observed, including pediatric participants having significantly greater linoleic acid levels at baseline. CONCLUSION: Ivacaftor reduces inflammatory PGE without fully correcting the plasma fatty acid abnormalities of CF. Age-related differences in fatty acid levels were observed, that may be a result of other clinical factors, such as diet, clinical care, or drug response.
BACKGROUND:Ivacaftor has produced significant improvement in certain individuals with cystic fibrosis (CF), though the full metabolic effects of treatment remain unknown. Abnormalities in fatty acid metabolism have previously been shown to be a characteristic of CFTR dysfunction. We hypothesized that as a reflection of this clinical improvement, ivacaftor would improve plasma fatty acid levels and decrease urine prostaglandin E metabolite levels. METHODS: This study analyzed plasma fatty acid levels and urine prostaglandin E metabolites (PGE-M) in 40 subjects with CF participating in the G551D observational (GOAL) study who demonstrated response to the medication by a significant decrease in sweat Cl levels. Paired samples were analyzed before and after 6months of ivacaftor treatment. RESULTS:Linoleic acid and docosahexaenoic acid levels, which are typically low in individuals with CF, did not significantly increase with ivacaftor treatment. However, arachidonic acid levels did decrease with ivacaftor treatment and there was a significant decrease in the arachidonic acid metabolite PGE-M as measured in the urine [median: before treatment 17.03ng/mg Cr; after treatment 9.06ng/mg Cr; p<0.001]. Furthermore, there were fatty acid age differences observed, including pediatric participants having significantly greater linoleic acid levels at baseline. CONCLUSION:Ivacaftor reduces inflammatory PGE without fully correcting the plasma fatty acid abnormalities of CF. Age-related differences in fatty acid levels were observed, that may be a result of other clinical factors, such as diet, clinical care, or drug response.
Authors: S D Freedman; M H Katz; E M Parker; M Laposata; M Y Urman; J G Alvarez Journal: Proc Natl Acad Sci U S A Date: 1999-11-23 Impact factor: 11.205
Authors: Ibrahim Batal; Mhd-Bassel Ericsoussi; Joanne E Cluette-Brown; Brian P O'Sullivan; Steven D Freedman; Juanito E Savaille; Michael Laposata Journal: Clin Chem Date: 2006-11-27 Impact factor: 8.327
Authors: Kelly F Thomsen; Michael Laposata; Sarah W Njoroge; Obi C Umunakwe; Waddah Katrangi; Adam C Seegmiller Journal: Lipids Date: 2011-05-05 Impact factor: 1.880
Authors: Drucy Borowitz; Barry Lubarsky; Michael Wilschanski; Anne Munck; Daniel Gelfond; Frank Bodewes; Sarah Jane Schwarzenberg Journal: Dig Dis Sci Date: 2015-08-07 Impact factor: 3.199
Authors: Steven D Freedman; Paola G Blanco; Munir M Zaman; Julie C Shea; Mario Ollero; Isabel K Hopper; Deborah A Weed; Andres Gelrud; Meredith M Regan; Michael Laposata; Juan G Alvarez; Brian P O'Sullivan Journal: N Engl J Med Date: 2004-02-05 Impact factor: 91.245
Authors: Charlotte M H H T Robroeks; Philippe P R Rosias; Dillys van Vliet; Quirijn Jöbsis; Jan-Bart L Yntema; Hein J L Brackel; Jan G M C Damoiseaux; Gertjan M den Hartog; Will K W H Wodzig; Edward Dompeling Journal: Pediatr Allergy Immunol Date: 2008-02-27 Impact factor: 6.377
Authors: Don B Sanders; Aliza Fink; Nicole Mayer-Hamblett; Michael S Schechter; Gregory S Sawicki; Margaret Rosenfeld; Patrick A Flume; Wayne J Morgan Journal: J Pediatr Date: 2015-09-02 Impact factor: 4.406
Authors: Deanne H Hryciw; Courtney A Jackson; Nirajan Shrestha; David Parsons; Martin Donnelley; Andrew J McAinch Journal: Cell Mol Life Sci Date: 2021-11-05 Impact factor: 9.261
Authors: Karen Keown; Ryan Brown; Declan F Doherty; Claire Houston; Michael C McKelvey; Shannice Creane; Dermot Linden; Daniel F McAuley; Joseph C Kidney; Sinéad Weldon; Damian G Downey; Clifford C Taggart Journal: Int J Mol Sci Date: 2020-09-02 Impact factor: 5.923
Authors: Benjamin L Wisniewski; Chandra L Shrestha; Shuzhong Zhang; Rohan Thompson; Myron Gross; Judith A Groner; Karan Uppal; Octavio Ramilo; Asuncion Mejias; Benjamin T Kopp Journal: J Cyst Fibros Date: 2020-05-30 Impact factor: 5.482
Authors: Valentine Sergeev; Frank Y Chou; Grace Y Lam; Christopher Michael Hamilton; Pearce G Wilcox; Bradley S Quon Journal: Ann Am Thorac Soc Date: 2020-02